Pranil K Chandra, DO, FCAP, FASCP
Senior Vice President and Chief Genomics OfficerIn 2011, joined PathGroup as Associate Medical Director of Molecular Pathology and now currently serves as Senior Vice President and Chief Genomics Officer at PathGroup. Holds board certifications in anatomic and clinical pathology, hematopathology and molecular genetic pathology. Read More
Completed AP/CP training and fellowships in hematopathology, oncologic pathology and molecular pathology at NYU Langone Medical Center and the University of Texas-MD Anderson Cancer Center, respectively. While at MD Anderson, served as Chief Fellow and received numerous awards for his research in acute myeloid leukemia. Has presented numerous abstracts and platform presentations at various pathology meetings and has published peer-reviewed articles and book chapters.
Additionally, a member of the American Society of Clinical Pathology, College of American Pathologists, and Association of Molecular Pathology where he also serves in a leadership capacity to the Economic Affairs Committee as Vice-Chair of Coverage. Is a recognized medical consultant in molecular pathology and personalized medicine and am considered a national thought leader in Precision Medicine and Cancer Genomics.
Jianyu Rao, MD, FCAP, FAcadTM, Physician
Professor and Vice Chair of the Department of Pathology at UCLA, Professor of Pathology and Epidemiology, Vice Chair of Technology and Innovation
A tenured full professor (Step 6) at David Geffen School of Medicine, University of California at Los Angeles. Currently serves as the vice chair of diagnostic technology innovation for the Department of Pathology and Laboratory Medicine, chief of cytopathology division, director of international telepathology, and medical director cytotechnology school. A fellow of College of American Pathologist (FCAP), fellow of Academy of Translational Medicine (FAcadTM), Member of Jonsson Comprehensive Cancer Center (JCCC), and Member of California Nanosystem Institute CNSI. Read More
Some recognitions are Physician of the Year award by Wall Street Journal (2005), International Health Professional and Scientist of the Year (2003, 2006), Guangji Scholar by Zhejiang University (2011), Southern California Super Doctors (2022 & 2023), and nominated to Shaw prize in life science and medicine (2010) and Tang prize (2018). Clinical expertise includes cytopathology, FNA, gynecological pathology, and genitourinary pathology. Research areas encompass cancer biomarker studies, cancer screen and precancer field disease study, molecular epidemiology, liquid biopsy, digital and computational pathology, with 208 peer-reviewed research publications, 18 books/book chapters, and speaking in over 200 meetings locally, nationally, and internationally.
Additional accomplishments include establishing the first-ever international Telepathology program, uncovering the role of cytoskeletal actin remodeling in cancer progression, determining molecular mechanisms of the anti-cancer effect of green tea, pioneering the work for developing cellular mechanobiological profiles as a biomarker for cancer, and spearheading the effort in applying AI/Machine Learning tools for cytological diagnosis of cancer – the “SMART” Cytology.